Home  |  Contact

Cellosaurus WM278 (CVCL_6473)

[Text version]

Cell line name WM278
Synonyms WM-278; WM 278; WC00054
Accession CVCL_6473
Resource Identification Initiative To cite this cell line use: WM278 (RRID:CVCL_6473)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: Wistar Institute melanoma cell line collection.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Heterozygous for BRAF p.Val600Glu (c.1799T>A) (PubMed=16827748; Wistar).
Hemizygous for PTEN deletion (Wistar).
HLA typing Source: PubMed=15592718
Class I
HLA-AA*02:01,26:01
HLA-BB*13:02,38:01
HLA-CC*06:02,12:03
Class II
HLA-DPDPB1*02:01:02,01:01:02
HLA-DQDQB1*06:03,02:01
HLA-DRDRB1*13:01,07:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.85
Native American0
East Asian, North0.99
East Asian, South2.12
South Asian1.13
European, North64.04
European, South30.87
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_6791 ! WM1617
Sex of cell Female
Age at sampling 62Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; ESTDAB; Wistar

Markers:
AmelogeninX
CSF1PO9
D2S133819,25
D3S135815
D5S81811
D7S8208,10
D8S117912,13
D13S31712
D16S53910,13
D18S5112,15
D19S43315,16
D21S1127,30
FGA19,22
TH016
TPOX8
vWA18,20

Run an STR similarity search on this cell line
Web pages https://www.wistar.org/our-scientists/meenhard-herlyn
http://www.rockland-inc.com/Product.aspx?id=51777
Publications

PubMed=4053039
Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D., Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H., Koprowski H.
Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Cancer Res. 45:5670-5676(1985)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A., Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958
Rose A.E., Poliseno L., Wang J., Clark M., Pearlman A., Wang G., Vega Y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I.
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.
Cancer Res. 71:2561-2571(2011)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cross-references
Cell line collections ATCC; CRL-2809 - Discontinued
Coriell; WC00054 - Discontinued
Cell line databases/resources CCLE; WM278_SKIN
Cell_Model_Passport; SIDM00975
Cosmic-CLP; 1240226
DepMap; ACH-002206
ESTDAB; ESTDAB-077
GDSC; 1240226
LINCS_LDP; LCL-1262
Ontologies BTO; BTO:0005480
CLO; CLO_0009616
Biological sample resources BioSample; SAMN03471796
Chemistry resources PharmacoDB; WM278_1671_2019
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM109035
GEO; GSM186479
GEO; GSM186480
GEO; GSM555133
GEO; GSM555172
GEO; GSM1670579
Other Wikidata; Q54994223
Polymorphism and mutation databases Cosmic; 686401
Cosmic; 972271
Cosmic; 1155544
Cosmic; 1995665
Cosmic; 2159427
Cosmic; 2163805
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number26